Wanbury Ltd. Share Price & Stock Analysis

Wanbury Ltd. (BSE: 524212) is a Navi Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹699 Cr, it ranks #1,809 by market cap among the 6,197 Indian listed companies on FinBizNet, and #26 of 63 in Pharmaceuticals. At ₹192.20 (as of 16 Nov 2026), the share price is 46.4% below its 52-week high of ₹358.85 and 19.0% above its 52-week low of ₹161.50. The share price is down 21.8% over one year and down 23.0% over three months.

Key Metrics

Current Price₹192.20
Market Cap₹699 Cr
BSE Code524212
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Pharmaceuticals
P/E Ratio10.4
Return on Equity64.92%
Return on Assets12.40%
52-Week Range₹161.50 – ₹358.85
1-Year Price Change-21.8%
3-Month Price Change-23.0%
Beta (1Y)0.36
Dividend Yield0.00%
HeadquartersNavi Mumbai, Maharashtra
Websitewww.wanbury.com

Latest Quarterly Results — Q2 FY27

Revenue₹183 Cr
Net Profit₹9 Cr
Net Margin4.7%
EPS (Basic)₹2.44
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Shareholding and Delivery

Promoters held 42.98% of Wanbury Ltd.'s shares as of Sept 2026, against 43.09% in Sept 2025 (−0.11 percentage points). Delivery averaged 48.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Wanbury Ltd.

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Products and Services

1. Pharmaceuticals and Related Products-This segment manufactures and sells formulations and active pharmaceutical ingredients.

Business Segments

1. Pharmaceuticals-100%

Wanbury Ltd. vs Peers — Pharmaceuticals

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Abbott India Ltd.₹56,531 Cr36.334.46%₹1,814 Cr-8.1%
Emcure Pharmaceuticals Ltd₹42,344 Cr47.919.57%₹2,820 Cr+73.3%
Ajanta Pharma Limited₹41,474 Cr39.425.39%₹1,794 Cr+27.8%
Piramal Pharma Ltd₹32,600 Crn/m-4.00%₹2,617 Cr+22.8%
RUBICON RESEARCH LIMITED₹28,526 Cr112.319.14%₹576 Cr+162.7%
Caplin Point Laboratories Ltdte₹18,155 Cr28.319.94%₹630 Cr+23.6%
Pfizer Ltd.₹17,811 Cr24.517.16%₹727 Cr-24.2%
Eris Lifesciences Ltd₹17,691 Cr28.318.07%₹892 Cr-17.5%
Wanbury Ltd.₹699 Cr10.464.92%₹183 Cr-21.8%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Wanbury Ltd.?

Wanbury Ltd. is trading at ₹192.20, with a market capitalisation of ₹699 Cr.

Which sector does Wanbury Ltd. belong to?

Wanbury Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).

What are the key financial ratios of Wanbury Ltd.?

Wanbury Ltd. has a P/E of 10.4 and a return on equity of 64.92%.

What is the stock symbol of Wanbury Ltd.?

Wanbury Ltd. is listed on the BSE under the scrip code 524212.

How has Wanbury Ltd.'s share price moved over the past year?

Wanbury Ltd.'s share price is down 21.8% over one year and down 23.0% over three months. Its 52-week range is ₹161.50 to ₹358.85.

What were Wanbury Ltd.'s latest quarterly results?

In Q2 FY27, Wanbury Ltd. reported revenue of ₹183 Cr and net profit of ₹9 Cr, with basic EPS of ₹2.44 (consolidated, parsed from the company's exchange filing).

What is the promoter holding in Wanbury Ltd.?

Promoters held 42.98% of Wanbury Ltd.'s shares as of Sept 2026, against 43.09% in Sept 2025 (−0.11 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.